BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $53
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst John McNulty has maintained an 'Outperform' rating on Chemours (NYSE:CC) but lowered the price target from $64 to $53.

August 04, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chemours' price target has been lowered from $64 to $53 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100